Vyne Therapeutics Inc. (VYNE) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Vyne Therapeutics Inc. (VYNE:NASDAQ), powered by AI.

Current Price
$0.63
Sector
Healthcare
What is the Vyne Therapeutics Inc. stock price forecast?

Vyne Therapeutics Inc. is currently trading at $0.63. View real-time AI analysis on Alpha Lenz.

What is Vyne Therapeutics Inc. insider trading activity?

View the latest insider trading data for Vyne Therapeutics Inc. on Alpha Lenz.

What is Vyne Therapeutics Inc.'s P/E ratio?

View Vyne Therapeutics Inc.'s valuation metrics on Alpha Lenz.

Vyne Therapeutics Inc.

NASDAQ · VYNE
$0.63+0.01(+1.75%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Vyne Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Vyne Therapeutics Inc.'s ROE is -66.3%. Explore profitability and growth together.

Ask for details

Company Overview

Vyne Therapeutics Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative dermatology solutions. Primarily focused on the treatment of skin diseases, Vyne Therapeutics leverages its proprietary technologies to address conditions such as acne and rosacea. The company's commitment to advancing dermatological research is evident in its pipeline of therapeutic products that aim to enhance the care and management of skin conditions. By working closely with healthcare professionals and leveraging partnerships within the pharmaceutical industry, Vyne Therapeutics strives to deliver effective treatment options that improve patient outcomes. As an active participant in the biopharmaceutical market, Vyne Therapeutics plays a critical role in advancing dermatological therapies, contributing to the broader medical and healthcare sectors by providing solutions that benefit consumers and practitioners alike.

CEOMr. David T. Domzalski
SectorHealthcare
IndustryBiotechnology
Employees13

Company Statistics

FY 2025

Profile

N/AMarket Cap
$570.00KRevenue
0.00Shares Out
13Employees

Margins

N/AGross
-5215.09%EBITDA
-5219.12%Operating
-4689.82%Pre-Tax
-4646.14%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

6.12%Rev 3Yr
-51.39%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-54.57%ROA
-66.33%ROE
-61.30%ROIC

Financial Health

$24.03MCash & Cash Equivalents
$-21.63MNet Debt
8.63%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Vyne Therapeutics Inc. (ticker: VYNE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 13 employees.

The current price is $0.633 with a P/E ratio of -x and P/B of -x.

ROE is -66.33% and operating margin is -5219.12%. Annual revenue is $570,000.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Vyne Therapeutics Inc. (VYNE) Stock Forecast 2026 $0.63 — Price, Financials & Analyst Targets | Alpha Lenz